Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cancer Research UK and Cancer Research Technology have entered into an agreement with Centella Therapeutics for the manufacturing and development of CEN-209 for cancer patients with solid tumors.
Subscribe to our email newsletter
CEN-209, the seventh drug candidate to enter Cancer Research UK’s Clinical Development Partnerships (CDP) scheme, is discovered at the Auckland Cancer Society Research Centre and exclusively licensed to Centella from Auckland Uniservices of New Zealand.
The cancer drug helps in destroying the tumor areas which are low in oxygen, when used along with radiotherapy and chemotherapy .
As per the terms of the pact, Cancer Research UK’s Drug Development Office is responsible to conclude the pre-clinical development and will also conduct the Phase I trial of the drug.
Following the Phase I trial Centella will have the exclusive option to buy back the clinical trial data and conduct further clinical studies towards approval of CEN-209.
If Centella does not exercise its option, the rights to the programme will be transferred to Cancer Research Technology to secure an alternative partner with the goal of making it possible for the drug to reach cancer patients.
Cancer Research UK Drug Development Office senior licensing manager Ian Walker said through this exciting partnership, they are taking a completely new drug which could treat a range of cancer types into clinical trials – bringing new hope for thousands of future cancer patients.
"We hope that the drug will enhance the effectiveness of radiotherapy, which is an incredibly important way to treat cancer as over 40% of cancer patients in the UK and 60% in the US receive radiotherapy as part of their treatment," Walker said.